Widespread patient access to innovative new products is being frustrated in non-U.S. markets by health technology assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in the U.S. — but what of their status elsewhere?
For example, only 35 of the 58 have been approved in the E.U. and of these many are tied up in HTA reviews. The commercial impact cannot be underestimated: with no predictable outcome, companies cannot plan effectively or understand the competitive environment in which they will operate. Which companies are being impacted? What products have made the grade? When — and where — will new competitive threats emerge?
Delivering a detailed report and usable data set, this ground breaking analysis exposes the pricing, reimbursement and HTA review status of innovative drugs in Australia, Canada, France, Germany and the U.K. for a clear picture of the competitive landscape.